ExpressionEdits Secures $13M in Seed Funding to Advance AI-Driven Protein Expression Optimization
ExpressionEdits aims to revolutionize protein expression for gene therapies by addressing production and manufacturing challenges.
Company Name: ExpressionEdits
Location: Cambridge, UK
Sector: Biotechnology
Funding Details: Raised $13M in Seed funding. The round was led by Octopus Ventures and redalpine, with participation from BlueYard Capital, Wilbe Capital, Acequia Capital, Amino Collective, and Hawktail.
Purpose of Investment: To accelerate candidate selection for preclinical studies and develop a pipeline of protein-based therapeutics.
Leadership: Founded by Dr. Kärt Tomberg, Professor Allan Bradley, and Dr. Liliana Antunes.
Technology: ExpressionEdits leverages proprietary intronization technology and its Genetic Syntax Engine, a computational gene editing platform that employs advanced AI to predict and redesign genes. This approach enhances protein expression and optimizes the effectiveness and precision of gene therapies. The technology allows for lower therapeutic doses, minimizing toxicity and improving targeting specificity.
About Company: ExpressionEdits, established in 2021, aims to revolutionize protein expression for gene therapies by addressing production and manufacturing challenges. The company's innovative approach enhances the genetic toolbox available for biotechnology applications, significantly advancing the field of recombinant protein therapies.